Dr. Shi has worked in biotech investing and advised biotech companies in various capacities, and was most recently an investor at F-Prime Capital prior to joining Mountainfield.
At F-Prime, Dr. Shi contributed to investments in healthcare companies across US, Europe and China, incubated new biotech companies, and managed portfolio companies. Her work involved multiple therapeutic areas including neuropsychiatry, oncology and immunology, and a variety of modalities including small molecules, ADCs, and cell and gene therapy. She was a board observer for several companies.
Before joining F-Prime, Dr. Shi worked in biomedical research at institutions including Stanford, Harvard and MIT. Dr. Shi has co-authored over thirty publications and received several fellowships and awards.
Dr. Shi holds a B.S. in Chemistry from Rice University, completed her MD, MBA and MS in epidemiology training at Stanford University.